Stocks in news: Infosys, Bajaj Auto, HDFC Life, Tata Communications, Angel One
Angel One's fourth-quarter profit rose 27% as trading activity helped more than make up for its higher spending amid heated competition for clients.
Equity markets extended decline for the third successive session and lost over half a percent, in continuation to the prevailing corrective move. In today's trade, shares of , , , , among others will be in focus due to various news developments and earnings.Infosys, , HDFC Life
Shares of , Bajaj Auto and HDFC Life will be in focus as the companies will announce their fourth quarter results.
Tata Communications
Tata Communications' consolidated profit declined marginally to Rs 321.55 crore in the fourth quarter ended March.
Read more: Here's the trade setup for today's session
Angel One
Angel One's fourth-quarter profit rose 27% as trading activity helped more than make up for its higher spending amid heated competition for clients.
Arbitral Tribunal allows JSW Energy subsidiary's claim to recover Rs 120 cr from Tamil Nadu Generation and Distribution Corporation (TANGEDCO).
The US FDA has issued an establishment inspection report (EIR) for Piramal Pharma’s Riverview manufacturing facility.
Biocon has signed licensing and supply agreement with Brazil-based Biomm for commercialisation of Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 Diabetes.
Ambuja
The promoters of the company Adani family has fully subscribed to the warrants program by further infusing Rs 8,339 crore thereby infusing total amount of Rs 20,000 crore.
ICICI Lombard's net profit rose 19% to Rs 520 crore for the quarter ended March. Gross premium jumped 22% to Rs 6,073 crore.
HDFC Bank board is likely to consider annual renewal of issuance of long-term bonds via private placement mode, according to reports.
Hathway Cable's net profit came in at Rs 35 crore in the March quarter as against a loss of Rs 14.6 crore in.
Infosys
Infosys has partnered with Belgium’s Proximus for Customer Service Management (CSM) operations.
USFDA has concluded Jubilant Pharmova’s Roorkee manufacturing facility inspection as ‘Voluntary Action Indicated’.
Source: Stocks-Markets-Economic Times
